EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology

Zande, Jessica J. van der; Gouw, Alida A.; Steenoven, Inger van; Scheltens, Philip; Stam, Cornelis J.; Lemstra, Afina W.

doi:10.3389/fnagi.2018.00190

Cited by 56 publications

(66 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not observe any group differences in dominant frequency variability which has previously been found to be increased in DLB patients compared to controls [12,17,19]. However, other studies have failed to replicate these findings [10,18,22], and our results further indicate that an increase in dominant frequency variability may not be a reliable feature of Lewy body disease.…”

Section: Discussioncontrasting

confidence: 70%

“…For each electrode separately, the mean power across all included epochs was estimated for different standard EEG frequency bands including delta (2-4 Hz), theta (4-5.5 Hz), pre-alpha (5.5-8 Hz), alpha (8)(9)(10)(11)(12)(13), and beta (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). Higher frequencies were excluded because these are particularly affected by muscular artifacts [11].…”

Section: Frequency Analysismentioning

confidence: 99%

See 1 more Smart Citation

Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies

et al. 2020

View full text Add to dashboard Cite

Objectives: To investigate using quantitative EEG the (1) differences between patients with mild cognitive impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer's disease (MCI-AD) and (2) its utility as a potential biomarker for early differential diagnosis. Methods: We analyzed eyes-closed, resting-state, high-density EEG data from highly phenotyped participants (39 MCI-LB, 36 MCI-AD, and 31 healthy controls). EEG measures included spectral power in different frequency bands (delta, theta, pre-alpha, alpha, and beta), theta/alpha ratio, dominant frequency, and dominant frequency variability. Receiver operating characteristic (ROC) analyses were performed to assess diagnostic accuracy. Results: There was a shift in power from beta and alpha frequency bands towards slower frequencies in the prealpha and theta range in MCI-LB compared to healthy controls. Additionally, the dominant frequency was slower in MCI-LB compared to controls. We found significantly increased pre-alpha power, decreased beta power, and slower dominant frequency in MCI-LB compared to MCI-AD. EEG abnormalities were more apparent in MCI-LB cases with more diagnostic features. There were no significant differences between MCI-AD and controls. In the ROC analysis to distinguish MCI-LB from MCI-AD, beta power and dominant frequency showed the highest area under the curve values of 0.71 and 0.70, respectively. While specificity was high for some measures (up to 0.97 for alpha power and 0.94 for theta/alpha ratio), sensitivity was generally much lower. Conclusions: Early EEG slowing is a specific feature of MCI-LB compared to MCI-AD. However, there is an overlap between the two MCI groups which makes it difficult to distinguish between them based on EEG alone.

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Frequency Analysismentioning

confidence: 99%

Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, functional imaging approaches are additional tools for visualizing the health and function of neurons affected by AD. EEG represents a dynamic measurement of synaptic function in cortical pyramidal neuronal dendrites that can capture the summed excitatory and inhibitory post-synaptic potentials at a macroscopic spatial scale with millisecond time resolution [134][135][136][137]. Overall, quantitative EEG analysis provides the most direct and dynamic clinical representation of neuronal and synaptic function in AD patients; however, while it is sensitive to changes in neuronal circuit responses resulting from synaptic dysfunction, it cannot discriminate between the exact mechanisms of action underlying synaptic dys/function.…”

Section: Biomarkers Of Synapse Damage or Lossmentioning

confidence: 99%

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

et al. 2020

View full text Add to dashboard Cite

Background: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of synapse damage or loss. The key points of this review include the following: Synapse loss is a downstream effect of amyloidosis, tauopathy, inflammation, and other mechanisms occurring in AD. Synapse loss correlates most strongly with cognitive decline in AD because synaptic function underlies cognitive performance. Compounds that halt or reduce synapse damage or loss have a strong rationale as treatments of AD. Biomarkers that measure synapse degeneration or loss in patients will facilitate clinical development of such drugs. The ability of methods to sensitively measure synapse density in the brain of a living patient through synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging, concentrations of synaptic proteins (e.g., neurogranin or synaptotagmin) in the cerebrospinal fluid (CSF), or functional imaging techniques such as quantitative electroencephalography (qEEG) provides a compelling case to use these types of measurements as biomarkers that quantify synapse damage or loss in clinical trials in AD. Conclusion: A number of emerging biomarkers are able to measure synapse injury and loss in the brain and may correlate with cognitive function in AD. These biomarkers hold promise both for use in diagnostics and in the measurement of therapeutic successes.

show abstract

“…The GTE score's sensitivity, specificity and area under receiver operating characteristics curve (AUROC) in differentiating probable DLB from AD were 72%, 85% and 0.9; and 79%, 76% and 0.78 at cut-off of 9.5 [26] and 6.5 [27], respectively. In particular, frontal intermittent rhythmic delta activities (FIRDA) was commonly found in DLB (17.2-33.3%) and less frequent in AD (1.8-5.6%) [26,27,49,50]. The adjusted odds ratio (aOR) for diagnosis of probable DLB (compared to AD) was 11.0-27.7 [26,27] when FIRDA is present.…”

Section: Dlb Vs Ad Visual Eeg Assessmentsmentioning

confidence: 99%

The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies—A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Despite improvements in diagnostic criteria for dementia with Lewy bodies (DLB), the ability to discriminate DLB from Alzheimer’s disease (AD) and other dementias remains suboptimal. Electroencephalography (EEG) is currently a supportive biomarker in the diagnosis of DLB. We performed a systematic review to better clarify the diagnostic and prognostic role of EEG in DLB and define the clinical correlates of various EEG features described in DLB. MEDLINE, EMBASE, and PsycINFO were searched using search strategies for relevant articles up to 6 August 2020. We included 43 studies comparing EEG in DLB with other diagnoses, 42 of them included a comparison of DLB with AD, 10 studies compared DLB with Parkinson’s disease dementia, and 6 studies compared DLB with other dementias. The studies were visual EEG assessment (6), quantitative EEG (35) and event-related potential studies (2). The most consistent observation was the slowing of the dominant EEG rhythm (<8 Hz) assessed visually or through quantitative EEG, which was observed in ~90% of patients with DLB and only ~10% of patients with AD. Other findings based on qualitative rating, spectral power analyses, connectivity, microstate and machine learning algorithms were largely heterogenous due to differences in study design, EEG acquisition, preprocessing and analysis. EEG protocols should be standardized to allow replication and validation of promising EEG features as potential biomarkers in DLB.

show abstract

EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology

Cited by 56 publications

References 46 publications

Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies

Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies—A Systematic Review

Contact Info

Product

Resources

About